Fresh off grant, Houston health tech company's AI aims to revolutionize diagnostics, care

data-driven

InformAI has three AI-based products geared at improving health care. Photo via Getty Images

In Houston, we’re lucky to have top-tier doctors in the Texas Medical Center, ready to treat us with the newest technology. But what about our family members who have to rely on rural hospitals? Thanks to one Houston company, doctors in smaller community hospitals may soon have new tools at their disposal that could improve outcomes for patients around the world.

Since InnovationMap last caught up with Jim Havelka, CEO of InformAI, two years ago, that hope has come far closer to a reality. InformAI is a VC-backed digital health company. Part of JLABS @ TMC innovation facilities, the company uses artificial intelligence to develop both diagnostic tools and clinical outcome predictors. And two of the company’s products will undergo FDA regulatory testing this year.

SinusAI, which helps to detect sinus-related diseases in CT scans, received its CE Mark — the European equivalent of FDA approval — last year and is being sold across the Atlantic today, says Havelka. He adds that in the United States alone, there are roughly 700,000 sinus surgeries that the product is positioned to support.

Another product, RadOnc-AI, is designed to help doctors prescribe radiation dose plans for head and neck cancers.

“Ideally the perfect plan would be to provide radiation to the tumor and nothing around it,” says Havelka. “We’ve built a product, RadOnc-AI, which autogenerates the dose treatment plan based on medical images of that patient.”

It can be an hours-long process for doctors to figure out the path and dose of radiation themselves, but the new product “can build that initial pass in about five minutes,” Havelka says.

That in itself is an exciting development, but because this technology was developed using the expertise of some of the world’s top oncologists, “the first pass plan is in line with what [patients would] get at tier-one institutions,” explains Havelka. This creates “tremendous equity” among patients who can afford to travel to major facilities and those that can’t.

To that end, RadOnc-AI was recently awarded a $1.55 million grant from the Cancer Prevention and Research Institute of Texas, or CPRIT, a state agency that funds cancer research. The Radiological Society of North America announced late last year that InformAI was named an Aunt Minnie Best of Radiology Finalist.

“It’s quite prestigious for our company,” says Havelka. Other recent laurels include InformAI being named one of the 10 most promising companies by the Texas Life Science Forum in November.

And InformAI is only gaining steam. A third product is earlier in its stage of development. TransplantAI will optimize donor organ and patient recipient matches.

“A lot of organs are harvested and discarded,” Havelka says.

His AI product has been trained on a million donor transplants to help determine who is the best recipient for an organ. It even takes urgency into account, based on a patient’s expected mortality within 90 days. The product is currently a fully functional prototype and will soon move through its initial regulatory clearances.

The company — currently backed by three VC funds, including DEFTA Partners, Delight Ventures, and Joyance Partners — is planning to do another seed round in Q2 of 2023.

“We’ve been able to get recognized for digital health products that can be taken to market globally,” says Havelka.

But what he says he’s most excited about is the social impact of his products. With more money raised, InformAI will be able to speed up development of additional products, including expanding the cancers that the company will be targeting. And with that, more and more patients will one day be treated with the highest level of care.

Prana Thoracic Inc., a medical device company developing a tool for early interception of lung cancer, announced a $3 million grant from CPRIT. Photo via Getty Images

Houston lung cancer diagnostics startup launches, snags $3M grant

cancer innovation

An oncology device company has secured a grant from the Cancer Prevention and Research Institute of Texas, the startup announced this week.

Houston-based Prana Thoracic Inc., a medical device company developing a tool for early interception of lung cancer, announced that Nucore Medical Inc., its wholly owned subsidiary, has been awarded a $3 million grant from CPRIT. The funding will support first-in-human studies and commercialization of Prana Thoracic’s technology.

“We’re excited to be recognized by CPRIT and believe this award speaks to the potential of Prana Thoracic’s surgical oncology devices,” says Joanna Nathan, CEO and founder of Prana Thoracic, in a news release. "This funding will accelerate our technology to the bedside, enabling us to provide Texans and patients all over the world with a definitive diagnosis of their pulmonary nodules earlier in their patient journey."

Prana Thoracic's technology is a minimally invasive, tissue-sparing nodulectomy tool that can evaluate suspicious pulmonary nodules early on in hopes of being able to catch and treat patients with lung cancer — the leading cause of cancer death in the United States, consisting of nearly 25 percent of all cancer deaths. The goal for Prana Thoracic is to equip physicians with the technology to more efficiently sample tissue from at-risk patients and dramatically improve outcomes.

“There has long been a gap between a simple needle biopsy of a nodule deep in the lung and opening the chest to remove a large segment of the lung to help diagnose early lung cancer, particularly when the nodules are very small,” says Dr. Edward Boyle, founder and one of the inventors of the technology, in the release. “As inventors, we partnered with the Johnson & Johnson MedTech Center for Device Innovation to help take this through design and early testing. At this point we are eager to advance the technology through first-in-human studies.”

Nathan, according to LinkedIn, left her role as manager of new ventures the Center for Device Innovation at the Texas Medical Center to pursue this new role at Prana Thoracic. She was at CDI for four years.

Joanna Nathan is back in the founder's seat. Photo via LinkedIn

These cancer research professionals just got fresh funding from a statewide organization. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Texas nonprofit cancer research funder doles out millions to health professionals moving to Houston

money moves

Thanks in part to multimillion-dollar grants from the Cancer Prevention and Research Institute of Texas, two top-flight cancer researchers are taking key positions at Houston’s Baylor College of Medicine.

Dr. Pavan Reddy and Dr. Michael Taylor each recently received a grant of $6 million from the Cancer Prevention and Research Institute of Texas (CPRIT).

Reddy is leaving his position as chief of hematology-oncology and deputy director at the University of Michigan’s Rogel Cancer Center to become director of the Baylor College of Medicine’s Dan L. Duncan Comprehensive Cancer Center. Dr. C. Kent Osborne stepped down as the center’s director in 2020; Dr. Helen Heslop has been the interim director.

Taylor, a pediatric neurosurgeon at the University of Toronto, is set to become the first-ever director of pediatric neuro-oncology research at Texas Children’s Hospital. The hospital is affiliated with the Baylor College of Medicine. Taylor is an expert in children’s brain tumors.

In all, 11 researchers recruited by three health care institutions in Houston recently received $34 million in CPRIT grants. The nine other grant recipients in Houston are:

Dr. Christine Lovly, M.D. Anderson Cancer Center, $4 million. She is co-leader of the Translational Research and Interventional Oncology Research Program at the Vanderbilt-Ingram Cancer Center in Nashville.
Hans Renata, Rice University, $4 million. He is an associate professor at UF Scripps Biomedical Research in Jupiter, Florida.
Mingjie Dai, Rice University, $2 million. He is a technology development fellow at Harvard University’s Weiss Institute for Biologically Inspired Engineering.
William Hudson, Baylor College of Medicine, $2 million. He is a postdoctoral fellow at Emory University in Atlanta.
Deepshika Ramanan, M.D. Anderson Cancer Center, $2 million. She is a research fellow in immunology at Harvard Medical School.
Jason Schenkel, M.D. Anderson Cancer Center, $2 million. He is an instructor in pathology at Harvard’s Brigham and Women’s Hospital.
Aria Vaishnavi, M.D. Anderson Cancer Center, $2 million. She is a postdoctoral scholar at the University of Utah’s Huntsman Cancer Institute.
Samantha Yruegas, Rice University, $2 million. She is a postdoctoral research associate at Princeton University in New Jersey.
Qian Zhu, Baylor College of Medicine, $2 million. He is a research fellow at Harvard’s Dana-Farber Cancer Institute.

A CPRIT committee recently approved 17 recruitment grants totaling nearly $48 million for cancer research institutions in Texas.

“CPRIT’s mission is to invest in the research prowess of Texas institutions while expediting breakthroughs in cancer cures and prevention … . These 17 highly respected researchers will join an impressive roster of cancer-fighters who call the Lone Star State home,” says Wayne Roberts, CEO of CPRIT.

Since its creation, CPRIT has awarded $2.9 billion in grants to cancer research organizations around the state.

A UH researcher has fresh funding to support her life-saving, cancer-fighting drug. Photo via UH.edu

University of Houston researcher receives grant for first-of-its-kind breast cancer drug

funds granted

A University of Houston researcher was awarded a $2 million grant from the Cancer Prevention and Research Institute of Texas to develop a new drug that will initially target breast cancer, the university announced this month.

The drug is intended to impact a type of traditionally "undraggable" target of cancer, known as intrinsically disordered proteins (IDPs), which researchers have yet to gain fundamental understanding of. According to the release, approximately 70 percent of proteins impacted by cancer are considered IDPs.

Gül Zerze, an assistant professor in the William A. Brookshire Department of Chemical and Biomolecular Engineering at the UH Cullen College of Engineering, has specialized in research on the computational modeling and simulations of these IDPs, and is one of the 12 cancer researchers awarded such a grant by the CPRIT.

Candidates for Zerze's drug will be rapidly tested through collaborations within UH and MD Anderson, according to the statement.

Gül Zerze is an assistant professor in the William A. Brookshire Department of Chemical and Biomolecular Engineering. Photo via UH.edu

"One out of nearly six Texas women diagnosed with breast cancer will die of the disease. Importantly, Texan women of color are disproportionately impacted by the high mortality rate compared to white Texan women (41 percent higher mortality rate reported for Black Texan women in 2016)," Zerze said in a statement. "This high mortality rate, despite the substantial efforts made for early diagnosis, calls for better therapeutics urgently.”

Zerze was recruited by the CPRIT to come to UH from Princeton last November. She was part of the latest class of recruitment grants from the organization, totaling $38 million to “form a critical ecosystem of distinguished cancer-fighting talent” in Texas.

According to the CPRIT website, the organization has recruited 263 cancer researchers and their labs to Texas over the years. First launched in 2007, the CPRIT is now a $6 billion, 20-year initiative that's allowing institutions in Houston compete against the likes of Harvard and Stanford universities, and the Cleveland and Mayo clinics.

“The ideas proposed here will save lives," Zerze said in the statement. "And the products that will come out of this project have a great potential for commercialization and founding companies to contribute to the Texas economy.”

Since 2009, institutions in Houston have employed CPRIT grants totaling more than $390 million to successfully recruit over 125 cancer researchers. Photo via Getty Images

With millions in grant funds, this nonprofit is making Houston an irresistible market for cancer researchers

attracting talent

In their bid to attract top-notch cancer researchers, institutions in Houston compete against the likes of Harvard and Stanford universities, and the Cleveland and Mayo clinics. Super-talented cancer researchers typically can choose from among dozens of institutions vying for them.

Yet cancer research centers in Houston and elsewhere in Texas wield a powerful advantage in this contest for talent — money.

As of early November, four cancer research centers in Houston — the University of Texas M.D. Anderson Cancer Center, University of Texas Southwestern Medical Center, Methodist Hospital Research Institute, and Baylor College of Medicine — had dangled grants totaling nearly $22 million to successfully lure nine high-profile cancer researchers this year to the Bayou City. The nonprofit Cancer Prevention & Research Institute of Texas (CPRIT), based in Austin, supplied the grants.

Since 2009, institutions in Houston have employed CPRIT grants totaling more than $390 million to successfully recruit over 125 cancer researchers, according to CPRIT data provided to InnovationMap. Houston has been the beneficiary of about half of all grants awarded to CPRIT scholars in Texas.

This year alone, four CPRIT scholars have landed at the UT Southwestern Medical Center as of early November, three at the Baylor College of Medicine, and one each at the Methodist Hospital Research Institute and MD Anderson Cancer Center. Each of the grants they received is around $2 million or $4 million.

According to CPRIT, Texas boasts a state-funded recruitment program for cancer researchers unmatched by another other state. Wayne Roberts, CEO of CPRIT, says the more than 250 CPRIT scholars recruited in the past 12 years throughout the state "are advancing research efforts, positioning Texas as a leader in the fight against cancer, and promoting economic development throughout the state."

Roberts is former associate vice president for public policy at the University of Texas Health Science Center in Houston.

Texans voted in 2007 to create CPRIT and invest $3 billion in the state's fight against cancer. Two years ago, Texans voted to pump another $3 billion into what now is a 20-year initiative. The institute bills itself as the largest state-based investment in cancer research in U.S. history and the world's second largest cancer research and prevention program.

Dr. Helen Heslop, interim director of the Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine, says the CPRIT grants give the cancer center an edge in wooing "highly sought after" cancer researchers, both senior and up-and-coming professionals. But the benefit goes well beyond that, according to Heslop.

"Having a new person who brings new skills and expertise is obviously great for the people who are working very closely with them at, say, our cancer center," she says. "But a lot of these people will also collaborate with other local institutions. … It just enriches the overall social environment between all the institutions."

On top of that, successfully recruiting high-caliber cancer researchers to Houston helps attract even more high-caliber cancer researchers, Heslop says.

Without the CPRIT grants, Houston would be less competitive in the hunt for first-rate cancer researchers, she says.

One factor that makes the CPRIT grants stand out is that they typically last five years, while other types of research grants frequently last only three years, Heslop says. This longer time span enables cancer researchers to undertake creative high-risk projects, offering them "a much longer runway to get themselves established" and then secure their own funding from organizations like the National Institutes of Health, she says. As a result, many cancer researchers who earn CPRIT grants wind up staying in Houston rather than being poached by research centers in other cities.

Dr. Qing Yi, director of the Center for Translational Research at Houston Methodist, received a $6 million CPRIT grant in 2018 that brought him back to Houston from the Cleveland Clinic's Lerner Research Institute. He specializes in research about multiple myeloma, the second most common blood cancer after non-Hodgkin's lymphoma. Gen. Colin Powell, former U.S. secretary of state, was battling multiple myeloma when he died in mid-October due to complications from COVID-19.

Yi says cancer research centers in Texas couple CPRIT grants with their own funding to up the ante in the competition for cancer researchers. This one-two financial punch is "way more generous" than funding offers from cancer research institutions in other states, according to Yi.

For example, the Methodist Hospital Research Institute successfully recruited researcher Yong Lu this year with the aid of a nearly $4 million CPRIT grant, paired with a 50 percent match of the institute's own money. Lu most recently ran a research lab at Wake Forest University's medical school that focuses on a type of cancer treatment known as adoptive cell immunotherapy.

Yi says his own CPRIT grant of $6 million was matched with $4 million from Houston Methodist, giving him a total funding pool of $10 million. Before heading to Cleveland, Yi was a tenured professor of medicine at the MD Anderson Cancer Center, meaning the CPRIT grant paved the way for his return to Houston. The $10 million pot of money "made it very attractive" to accept the Houston Methodist offer, he says.

"CPRIT funding is really crucial for Texas to recruit top-notch cancer investigators into our state. It's one of the best things that Texas has done for cancer research," Yi says.

Three health and tech research projects coming out of the Houston area have received grants to continue their work. Getty Images

These 3 Houston-area researchers receive millions in grants for ongoing innovation projects

Research roundup

Money makes the world go 'round, and that's certainly the case with research projects. Grants are what drives research at academic institutions across the country and fuel the next great innovations.

These three projects coming out of Houston-area universities were all granted multimillion-dollar sums in order to continue their health tech, cancer-prevention, and even electric vehicle battery research projects,

University of Houston's $3.2 million grant for its next-generation micro CT scan

Associate professor of physics Mini Das developed a better way to approach CT scans. Photo via uh.edu

In an effort to improve imaging and lower radiation, Mini Das, associate professor of physics at the University of Houston, is moving the needle on introducing the next generation of micro computed tomography (CT) imaging. Das recently received a five-year, $3.2 million grant from the National Institute of Biomedical Imaging and Bioengineering to help move along her work in this field.

"This has the potential to transform the landscape of micro-CT imaging," says Das in a news release.

Das is responsible for developing the theory, instrumentation and algorithms for spectral phase-contrast imaging (PCI) that allows for lower radiation with higher image details, according to the release.

"Current X-ray and CT systems have inherent contrast limitations and dense tissue and cancer can often look similar. Even if you increase the radiation dose, there is a limit to what you can see. In addition, image noise becomes significant when increasing resolution to see fine details, often desirable when scanning small objects," says Das.

Rice University researcher's $2.4 million grant to advance on car batteries

This company’s machine learning programs are making driving in Houston safer — and cheaper

A Rice University scientist is looking to optimize car batteries. Pexels

A Rice University scientist is working toward improving batteries for electric vehicles. Materials scientist Ming Tang and his colleagues — backed by a $2.4 million grant from the United States Advanced Battery Consortium — are working on a project led by Worcester Polytechnic Institute (WPI) in Massachusetts, which will run for 36 months and will focus on low-cost and fast-charging batteries.

"Traditional battery electrodes are prepared by the slurry casting method and usually have uniform porosity throughout the electrode thickness," says Tang, an assistant professor of materials science and nanoengineering, in a news release. "However, our earlier modeling study shows that an electrode could have better rate performance by having two or more layers with different porosities.

"Now with the Missouri University of Science and Technology and WPI developing a new dry printing method for battery electrode fabrication, such layered electrodes can be manufactured relatively easily," he said. Tang's group will use modeling to optimize the structural parameters of multilayer electrodes to guide their fabrication.

The academics will also work with a manufacturer, Microvast, that will assemble large-format pouch cells using layered electrodes and evaluate the electrochemical performance against the program goals, according to the release.

"The public/private partnership is critical to steer the research performed at universities," Tang says. "It helps us understand what matters most to commercial applications and what gaps remain between what we have and what is needed by the market. It also provides valuable feedback and gives the project access to the state-of-the-art commercial battery fabrication and testing capabilities."

Texas A&M faculty member's $5 million grant for cancer research

Tanmay Lele of Texas A&M University is looking at how cells react to mechanical forces in cancer. Photo via tamu.edu

Tanmay Lele, a new faculty member in Texas A&M University's Department of Biomedical Engineering, received a $5 million Recruitment of Established Investigators grant from the Cancer Prevention and Research Institute of Texas (CPRIT) in May to research how cancer progresses.

More specifically, Lele's research focuses on mechanobiology and how cells sense external mechanical forces as well as how they generate mechanical forces, and how these mechanical forces impact cell function, according to a news release from A&M.

"The nuclei in normal tissue have smooth surfaces, but over time the surfaces of cancer nuclei become irregular in shape," Lele says in the release. "Now, why? Nobody really knows. We're still at the tip of the iceberg at trying to figure this problem out. But nuclear abnormalities are ubiquitous and occur in all kinds of cancers — breast, prostate and lung cancers."

Lele will work from two laboratories — one in College Station and one in the Texas A&M Health Science Center's Institute of Biosciences & Technology in Houston. THe will collaborate with Dr. Michael Mancini and Dr. Fabio Stossi from Baylor College of Medicine.

"Like any other basic field, we are trying to make discoveries with the hope that they will have long-term impacts on human health," Lele says.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Med tech firm expands footprint, Houston innovator assumes new role, and more local innovation news

short stories

Houston's innovation ecosystem has had some big news this month, from new job titles for Houston innovators to expanding office space.

In this roundup of Houston startup and innovation news, a Houston organization expands its footprint in the TMC, Rice University opens applications for a cleantech accelerator, and more.

Organization expands footprint in Houston

Proxima CRO has announced its expansion within TMCi. Photo via Twitter

Proxima Clinical Research, a contract research organization headquartered in Houston, announced that it is expanding its office space in the Texas Medical Center Innovation Factory.

"Texas Medical Center is synonymous with innovation, and the TMC Innovation space has proven an ideal location for our CRO. It's an important part of our origin story and a big part of our success," says Kevin Coker, CEO and co-founder of Proxima CRO, in a news release.

The expansion will include around 7,500-square feet of additional office space.

"The resources found across TMC's campuses allow for companies such as Proxima Clinical Research to achieve clinical and business milestones that will continue to shape the future of life sciences both regionally and globally. We are excited for Proxima to expand their footprint at TMC Innovation Factory as they further services for their MedTech customers," says Tom Luby, director of TMC Innovation, in the release.

$20M grant fuels hardtech program's expansion

Activate is planting its roots in Houston with a plan to have its first set of fellows next year. Photo via Activate.org

A hardtech-focused nonprofit officially announced its Houston expansion this week. Activate, which InnovationMap reported was setting up its fifth program here last month, received a $20M commitment by the National Science Foundation to fuel its entrance into the Bayou City.

“Houston’s diversity offers great promise in expanding access for the next generation of science entrepreneurs and as a center of innovation for advanced energy," says NSF SBIR/STTR program director Ben Schrag in a news release.

The organization was founded in Berkeley, California, in 2015 to bridge the gap between the federal and public sectors to deploy capital and resources into the innovators creating transformative products. The nonprofit expanded its programs to Boston and New York before launching a virtual fellowship program — Activate Anywhere, which is for scientists 50 or more miles outside one of the three hubs.

“We are delighted to be opening our newest Activate community in Houston,” says Activate Anywhere managing director Hannah Murnen, speaking at the annual Advanced Research Projects Agency-Energy Innovation Summit. “Houston is a city where innovation thrives, with an abundance of talent, capital, and infrastructure—the perfect setting for the Activate Fellowship.”

Activate is still looking its Houston’s first managing director is actively underway and will select fellows for Activate Houston in 2024.

TMC names new entrepreneur in residence

Zaffer Syed has assumed a new role at TMC. Photo via TMC.org

Houston health tech innovator has announced that he has joined the Texas Medical Center's Innovation Factory as entrepreneur in residence for medtech. Zaffer Syed assumed the new role this month, according to his LinkedIn, and he's been an adviser for the organization since 2017.

Syed has held a few leadership roles at Saranas Inc., a medical device company founded in Houston to detect internal bleeding following medical procedures. He now serves as adviser for the company.

"As CEO of Saranas, he led the recapitalization of the company that led to the FDA De Novo classification and commercial launch of a novel real-time internal bleed monitoring system for endovascular procedures," reads the TMC website. "Zaffer oversaw clinical development, regulatory affairs and strategic marketing at OrthoAccel Technologies, a private dental device startup focused on accelerating tooth movement in patients undergoing orthodontic treatment.

"Prior to working in startup ventures, Zaffer spent the first 13 years of his career in various operational roles at St. Jude Medical and Boston Scientific to support the development and commercialization of Class III implantable devices for cardiovascular and neuromodulation applications."

TMC is currently looking for an entrepreneur in residence for its TMCi Accelerator for Cancer Therapeutics program.

Applications open for clean energy startup program

Calling all clean energy startups. Photo courtesy of The Ion

The Clean Energy Accelerator, an energy transition accelerator housed at the Ion and run by the Rice Alliance for Technology and Entrepreneurship, has opened applications for Class 3. The deadline to apply is April 14.

The accelerator, which helps early-stage ventures reach technical and commercial milestones through hybrid programming and mentorship, will host its Class 3 cohort from July 25 to Sept. 22.

“Accelerating the transition to a net-zero future is a key goal at Rice University. Through accelerating the commercial potential of our own research as well as supporting the further adoption of global technologies right here in Houston, the Rice Alliance Clean Energy Accelerator is proof of that commitment,” says Paul Cherukuri, vice president of innovation at Rice, in a news release. “The Rice Alliance has all the critical components early-stage energy ventures need for success: a corporate innovation network, energy investor network, access to mentors and a well-developed curriculum. This accelerator program is a unique opportunity for energy startups to successfully launch and build their ventures and get access to the Houston energy ecosystem.”

According to Rice, the 29 alumni companies from Class 1 and 2 have gone on to secure grants, partnerships, and investments, including more than $75 million in funding. Companies can apply here, learn more about the accelerator here or attend the virtual information session April 3 by registering here.

Houston-based real estate giant rolls out sustainability-focused business unit

seeing green

Houston-based real estate investor, developer, and manager Hines is stepping up its commitment to sustainability.

The company just formed a business unit, EXP by Hines, that is aimed at addressing “the disruptive changes in the built environment.”

EXP by Hines comprises two parts: Global ESG and the Global Venture Lab. Doug Holte, who was a senior partner at Hines from 1987 to 2009, has been hired as CEO of EXP.

“EXP by Hines is an engine of growth using the most innovative ideas in capital, culture, and environmental stewardship to connect every stakeholder in the built environment and create healthy, activated communities,” Holte says in a news release. “EXP is looking beyond the boundaries of real estate to solve complex problems while creating long-term value.”

Peter Epping, who joined Hines in 2001, is the company’s global head of ESG (environmental, social, and governance). A 2022 survey by professional services firm Deloitte found that ESG continues to gain ground in the corporate world. Business executives questioned for the survey believe ESG strategies will:

Strengthen stakeholder trust
Elevate brand reputation
Boost employee retention
Improve ROI
Reduce risk

Kathryn Scheckel, who joined Hines in 2019, leads the company’s new Global Venture Lab, which is tasked with identifying and accelerating ventures, partnerships and investments. The lab includes a startup incubator and a VC arm.

According to the news release, priorities of the Global Venture Lab include innovations in the use of physical space, development of ESG solutions, and creation of “revolutionary built-world technologies.”

The efforts being spearheaded by Holte, Epping, and Scheckel are geared in part toward Hines achieving net zero carbon by 2040 in its nearly 231 million-square-foot global portfolio without buying carbon credits.

5 most popular innovation stories in Houston this week

what's trending

Editor's note:Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup news on InnovationMap included high-tech space suits revealed, tips from a unicorn startup founder, and more.

Houston space tech company secures third NASA mission, reveals new spacesuits

Axiom Space has announced plans for its third commercial space launch and revealed details of its high-tech spacesuit. Photo courtesy of NASA

A Houston-based space tech company has revealed details on two of its commercial partnerships with NASA.

NASA and Axiom Space have again signed a mission order for a private astronaut mission to the International Space Station. The mission will commence sometime in November or on and will be from the agency’s NASA’s Kennedy Space Center in Florida. Axiom Mission 3 is the third mission of its kind and, according to a statement from NASA, is expected to be a 14-day trip.

The ISS's Multilateral Crew Operations Panel will approve four proposed crew members and two back up crew submitted by Axiom for the Ax-3 mission. The crew will be expected to train for their flight with NASA, international partners, and SpaceX beginning this spring, according to NASA.

“Axiom Space’s selection to lead the next private astronaut mission to the International Space Station enables us to continue expanding access to nations, academia, commercial entities, and emerging industries to research, test, and demonstrate new technologies in microgravity,” says Michael Suffredini, CEO and president of Axiom Space, in the release. “As NASA’s focus shifts back to the Moon and on to Mars, we are committed to transforming low-Earth orbit into a global space marketplace, where access to space moves beyond the partners of the space station to nations, institutions and individuals with new ideas fueling a thriving human economy beyond Earth.” Read more.

7 lessons from a Houston-based unicorn startup founder

Gaurab Chakrabarti, the CEO and co-founder of Solugen, shared his entrepreneurial journey on the SXSW stage this year. Photo courtesy of the Greater Houston Partnership

At a fireside chat at SXSW, a Houston founder pulled back the curtain on his entrepreneurial journey that's taken him from an idea of how to make the chemicals industry more sustainable to a company valued at over $2 billion.

Gaurab Chakrabarti, the CEO and co-founder of Solugen, joined the Greater Houston Partnership's Houston House at SXSW on Monday, March 13, for a discussion entitled, "Building a Tech Unicorn." In the conversation with Payal Patel, principal of Softeq Ventures, he share the trials and tribulations from the early days of founding Solugen. The company, which has raised over $600 million since its founding in 2016, has an innovative and carbon negative process of creating plant-derived substitutes for petroleum-based products. Read more.

Following Silicon Valley Bank collapse, banking diversification is key for Houston founders

Last weekend was a tumultuous one for founders and funders in Houston and beyond. Here's what lessons were learned. Photo via Getty Images

Last week, Houston founder Emily Cisek was in between meetings with customers and potential investors in Austin while she was in town for SXSW. She was aware of the uncertainty with Silicon Valley Bank, but the significance of what was happening didn't hit her until she got into an Uber on Friday only to find that her payment was declined.

“Being positive in nature as I am, and with the close relationship that I have with SVB and how they’ve truly been a partner, I just thought, ‘OK, they’re going to figure it out. I trust in them,'” Cisek says.

Like many startup founders, Cisek, the CEO of The Postage, a Houston-based tech platform that enables digital legacy planning tools, is a Silicon Valley Bank customer. Within a few hours, she rallied her board and team to figure out what they needed to do, including making plans for payroll. She juggled all this while attending her meetings and SXSW events — which, coincidentally, were mostly related to the banking and fintech industries. Read more.

California-founded biotech startup relocates to join Houston's emerging bioeconomy

San Diego-based rBIO moved to Houston to take advantage of the growing ecosystem of biomanufacturing and synthetic biology. Photo via Getty Images

Cameron Owen had an idea for a synthetic biology application, and he pitched it to a handful of postdoctoral programs. When he received the feedback that he didn't have enough research experience, he decided to launch a startup based in San Diego around his idea. He figured that he'd either get the experience he needed to re-apply, or he'd create a viable company.

After three years of research and development, Owen's path seems to have taken him down the latter of those two options, and he moved his viable company, rBIO, to Houston — a twist he didn't see coming.

“Houston was not on my radar until about a year and a half ago,” Owen says, explaining that he thought of Houston as a leading health care hub, but the coasts still had an edge when it came to what he was doing. “San Diego and the Boston area are the two big biotech and life science hubs.” Read more.

Investor advocates now is the time to position Houston as a leading biomanufacturing hub

Veronica Wu, founder of First Bight Ventures, joins the Houston Innovators Podcast to outline Houston's opportunities in synthetic biology and biomanufacturing. Photo courtesy

Houston has all the ingredients to be a successful synthetic biology hub, says Veronica Wu. She believes so strongly in this that she relocated to Houston from Silicon Valley just over a year ago to start a venture capital firm dedicated to the field. Since then, she's doubled down on her passion for Houston leading in biotech — especially when it comes to one uniquely Houston opportunity: biomanufacturing.

While Houston's health care innovation scene is actively deploying synthetic biology applications, Wu points to Houston-based Solugen, a plant-based chemical producer, as an example of what Houston has to offer at-scale industrial biomanufacturing. Houston has the workforce and the physical space available for more of these types of biomanufacturing plants, which have a huge potential to move the needle on reducing carbon emissions.

"This is really fundamental technology that's going to change the paradigm and whole dialogue of how we are making a significant impact in reducing a carbon footprint and improving sustainability," says Wu, founder and managing partner of First Bight Ventures, on the Houston Innovators Podcast. Read more.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME